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ABSTRACT
Purpose: In endometrial cancer, loss of progesterone
receptors (PR) is associated with more advanced disease.
This study aimed to investigate the mechanism of action of
progesterone and the loss of its receptors (PRA and PRB) in
development of endometrial cancer.
Experimental Design: A 9600-cDNA microarray analy-
sis was performed to study regulation of gene expression in
the human endometrial cancer subcell line Ishikawa
PRAB-36 by the progestagen medroxy progesterone acetate
(MPA). Five MPA-regulated genes were selected for addi-
tional investigation. Expression of these genes was studied
by Northern blot and by immunohistochemistry in Ishikawa
subcell lines expressing different PR isoforms. Additionally,
endometrial cancer tissue samples were immunohistochemi-
cally stained to study the in vivo protein expression of the
selected genes.
Results: In the PRAB-36 cell line, MPA was found to
regulate the expression of a number of invasion- and metas-
tasis-related genes. On additional investigation of five of
these genes (CD44, CSPG/Versican, Tenascin-C, Fibronec-
tin-1, and Integrin- 1), it was observed that expression and
progesterone regulation of expression of these genes varied
in subcell lines expressing different PR isoforms. Further-
more, in advanced endometrial cancer, it was shown that
loss of expression of both PR and E-cadherin was associated
with increased expression CD44 and CSPG/Versican.
Conclusion: The present study shows that progestagens
exert a modulatory effect on the expression of genes involved
in tumor cell invasion. As a consequence, loss of PR expres-
sion in human endometrial cancer may lead to development
of a more invasive phenotype of the respective tumor.
INTRODUCTION
Endometrial cancer is one of the most common gyneco-
logical malignancies in Europe and the United States. As many
as 70% of the patients can be cured (1), mostly by surgery
(hysterectomy with additional salpingo-oophorectomy), often in
combination with radiotherapy. The remaining patients have
already developed distant metastases or will develop recurrent
disease. For palliative treatment of these patients, and for treat-
ment of premenopausal patients who want to preserve fertility,
high-dose progesterone is prescribed because of the growth-
inhibiting effects of this hormone on the endometrium (1–3).
However, in 80–90% of patients with more progressed disease
this therapy is not beneficial, because the tumor has become
unresponsive to progesterone.
Progesterone can act on the endometrium through activa-
tion of progesterone receptor A and B (PRA and PRB),3 which
belongs to the family of nuclear receptors. Transcription of the
hPR gene is under regulation of two different promoters (4).
Transcription initiation from these two promoters results in two
distinct mRNAs, which are translated into two distinct proteins:
hPRA and hPRB. The hPRA is a truncated form of hPRB,
lacking the first 164 amino acid residues at the NH2 terminus.
The hPRA and hPRB can be considered as two independent
receptors, which display different transcriptional activities. Veg-
eto et al. (5) have described that hPRA is not as transcriptionally
active as is hPRB, and that hPRA may have a more important
function as a cell- and promoter-specific repressor of hPRB (6).
Furthermore, it has been described that a different set of genes
is regulated by progesterone in human breast (7) and endome-
trial (8) cancer cells that express different PR isoforms.
Several functional domains can be recognized in hPRA and
hPRB. These PR isoforms have in common two transcription
AFs, AF-1 and AF-2, and one inhibitory domain. In hPRB, a
third AF (AF-3) has been defined in the NH2-terminal amino
acid stretch. According to Giangrande et al. (9) this hPRB-
specific AF-3 domain suppresses the activity of the inhibitory
domain. Whereas the function of the inhibitory domain in hPRB
is neutralized by AF-3, in hPRA the inhibitory domain is still
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functional in inhibiting transcriptional activity. In support of this
view, Giangrande et al. (6) have shown that in contrast to hPRB,
hPRA was unable to recruit coactivators. In addition to the
functional difference of both isoforms, hPRA and hPRB are
reported to be located in different cellular compartments in the
absence of ligand. Lim et al. (10) found that unliganded green
fluorescent protein-labeled hPRA is localized predominantly in
the nucleus, whereas unliganded green fluorescent protein-
labeled hPRB is mainly present in the cytoplasm. On activation
by ligand, both receptors are exclusively located in the nu-
cleus (10).
In general, literature agrees on a loss of PR in endometrial
cancer (11–19), but reports are conflicting whether this is a
consequence of selective down-regulation of hPRA or hPRB, or
of both receptors. Fujimoto et al. (17) reported that in advanced
tumors, hPRA could not be detected. In accordance with this,
the same group later described that in distant metastases of
endometrial cancer, it is hPRB that is expressed predominantly
(18). Arnett-Mansfield et al. (19) found a reduced expression of
either one or both of the two PR isoforms in the majority of
endometrial tumors, compared with hyperplastic or normal en-
dometrial tissue. In addition, hypermethylation of PRB alleles
(20) and expression of exon-deleted PR mRNA (21) have been
described in endometrial cancer tissue.
To make it possible to differentiate between the effects of
the two isoforms of the PR, we previously transfected the
well-differentiated human endometrial cancer cell line Ishikawa
to stably express either hPRA or hPRB, or both isoforms of the
receptor.4 Making use of this model, we studied differences in
expression of metastasis-related genes in the different Ishikawa
subcell lines. Using endometrial cancer tissue samples we stud-
ied the expression of these genes in relation to the loss of
progesterone receptors in vivo.
MATERIALS AND METHODS
Cell Culture. Ishikawa endometrial cancer cells (clone
3H12, additionally referred to as IKpar) were obtained from Dr.
Masato Nishida (Kasumigaura National Hospital, Tsuchiura,
Ibarakiken, Japan) and maintained in DMEM/F12 (Life Tech-
nologies, Inc., Carlsbad, CA), supplemented with 10% v/v FCS
(Life Technologies, Inc.) and penicillin/streptomycin. The sub-
cell lines that are used are IKpar cells that have been stably
transfected with hPRA (line PRA-1), hPRB (line PRB-1), or
both receptors (line PRAB-36), as described previously by
Smid-Koopman et al.4 These subcell lines were cultured under
similar conditions and in similar media as the IKpar cells, but
with the addition of neomycin (500 g/ml; ICN) and hygromy-
cin (250 g/ml; Invitrogen Corporation, Carlsbad, CA) to main-
tain selection pressure for the transfected human progesterone
receptors. This selection pressure was maintained throughout
the experiments. Before all of the experiments, cells were cul-
tured for 72 h in medium where FCS was substituted by 5% v/v
DCC-FCS. Culture passages 15–25 were used in the experi-
ments.
cDNA Microarray. PRAB-36 cells were cultured for
48 h in DMEM/F12 supplemented with 5% v/v DCC-FCS,
either in the presence or absence of progestagen, i.e. 107 M
MPA (Sigma, St. Louis, MO). RNA was isolated according to
Auffray and Rougeon (22), and shipped to Incyte Genomics,
Inc. (St. Louis, MO), where a 9600 cDNA microarray analysis
(Human UniGene1) was performed. Results were analyzed us-
ing Incyte GEMTools 2.5.0.
Northern Blot. Cells were cultured as described in the
presence of 107 M MPA for 0, 8, 24, 48, or 72 h. RNA was
isolated as described above, separated on a 1.5% w/v agarose
gel and blotted onto Hybond membrane (Amersham Bio-
sciences Europe, Roosendaal, the Netherlands). The following
[32P]dATP-labeled cDNA probes were hybridized to the blots:
CD44: image713145, 549-bp; Fibronectin-1: image139009,
383-bp (both acquired from Dr. Guido Jenster, Department of
Urology, Erasmus MC, Rotterdam, the Netherlands); Integrin-
1: image PRB-118212, 136-bp; Tenascin-C: image P107816,
437-bp; and CSPG/Versican: image N038145, 470-bp (all ac-
quired from RZPD, Berlin, Germany). To verify equal loading,
an actin-probe (an 1100-bp PstI fragment from hamster -actin
cDNA) was hybridized to the blots.
Collagen Gel Culture. To study protein expression in
the different subcell lines, cells were seeded and cultured in
collagen gels. Rat tail tendon collagen (final concentration in the
gel: 3.0 mg/ml; collagen kindly provided by Dr. Bert Neder-
bragt, Department of Veterinary Pathology, Utrecht University,
Utrecht, the Netherlands) was mixed with 5 concentrated culture
medium (DMEM/F12 supplemented with 5% DCC-FCS) con-
taining 19% v/v 0.11 M NaOH. Mixing was performed on ice to
prevent premature polymerization of the gel. To the mixture,
cells were added (final concentration in the gel: 2  106 cells/ml),
and resuspended to ensure equal distribution of the cells throughout
the gel. The collagen/cell mixture was poured in 24-wells plates,
and the gels were allowed to polymerize in a 37°C incubator before
culture medium was added. Cells were cultured in DCC-FCS-
supplemented medium for 72 h in the presence or absence of
107 M MPA. The gels were fixed in formalin and embedded in
paraffin to mimic fixation and embedding procedures used in
preservation of tissue samples.
Tissue Samples. Tissue samples involved formalin-
fixed, paraffin-embedded samples of endometrioid adenocarci-
noma, obtained from the Department of Pathology from the
Erasmus MC. Histological typing and grading (according to the
modified FIGO staging system; Ref. 23) and extent of myome-
trial invasion were assessed by the Erasmus MC Department of
Pathology.
Immunohistochemistry. Sections of formalin-fixed,
paraffin-embedded tissue samples and of collagen gels contain-
ing IKpar, PRA-1, PRB-1, or PRAB-36 cells were deparaf-
finized, and endogenous peroxidase activity was inhibited by
treatment with 4% v/v H2O2 in methanol for 20 min. Antigen
retrieval was performed in a microwave oven in 10 mM citric
acid buffer (pH 6.0) for 3  5 min. Slides were allowed to cool
to room temperature and washed three times in PBS before
being incubated for 20 min in PBS containing 10% v/v blocking
4 E. Smid-Koopman, E. C. M. Kuhne, E. Hanekamp, S. Gielen, P. E. De
Ruiter, J. A. Grootegoed, T. J. M. Helmerhorst, C. W. Burger, A. O.
Brinkmann, F. J. Huikeshoven, and L. J. Blok. Progesterone regulation
of growth and gene expression in human endometrial carcinoma cell
lines, submitted for publication.
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serum. Normal goat serum (DAKO, Glostrup, Denmark) was
used as blocking serum for the mouse monoclonal antibodies,
and normal rabbit serum (DAKO) was used as blocking serum
for the goat polyclonal antibody. The following antibodies were
used: anti-PRAB: hPRa8; anti-PRB: hPRa2 (both acquired from
NeoMarkers, Fremont, CA); anti-E-cadherin: G10/sc-8426;
anti-CD44: DF1485/sc-7297; anti-Integrin-1: 4B7R/sc-9970;
anti-Tenascin-C: N-19/sc-9871 (all acquired from SantaCruz
Biotechnology, Santa Cruz, CA); anti-CSPG: CS-56 (Sigma);
and anti-Fibronectin-1: FBN11 (NeoMarkers). The primary an-
tibodies were diluted 1:200 in PBS containing 1% v/v blocking
serum for tissue slides, and 1:1000 (PRAB antibody) or 1:500
(other) in PBS containing 1% v/v blocking serum for the slides
of collagen gels containing the subcell lines. Incubation with
primary antibody occurred overnight at 4°C. Antibodies were
detected indirectly with biotin-labeled goat-antimouse or rabbit-
antigoat antibodies (DAKO) 1:400 in PBS containing 1% v/v
blocking serum for 30 min at room temperature, followed by
StreptABComplex (DAKO) 1:1:200 in PBS (30 min at room
temperature). Staining was developed with 3,3-diaminobenzi-
dine/concentrated metal complex (Pierce, Rockford, IL). Slides
were counterstained with hematoxilin, dehydrated, and
mounted.
Expression of the proteins was approached semiquantita-
tively by visual estimation. Four categories of expression were
used: :  80% positive; : 60–80% positive; : 30–60%
positive; and : 	 30% positive.
Western Blot. PRAB-36 cells were cultured for 0, 8, 24,
48, or 72 h in the presence of 107 M MPA. Cells were washed
twice with PBS, after which the culture flasks were placed at
80°C overnight. Cells were lysed with RIPA buffer [40 mM
Tris-HCl (pH 7.4), 5 mM EDTA, 10% glycerol, 10 mM sodium
phosphate, 10 mM sodium molybdate, 50 mM NaF, and 0.5 mM
sodium orthovanadate], containing 10 mM DTT, 1% Triton X-100,
0.08% SDS, 0.5% sodium deoxycholate, and 1 complete prote-
ase inhibitors (Roche Diagnostics GmbH, Mannheim, Germany).
The lysates were centrifuged at 1000  g for 40 min, after which
the pellet was discarded. Equal protein samples were separated on
7% polyacrylamide gels and transferred onto a nitrocellulose mem-
brane. The membrane was blocked for 1 h in blocking buffer
(PBS/Tween containing 5% nonfat milk powder) and incubated
overnight at 4°C with a mouse monoclonal antibody recognizing
Fibronectin-1 (clone EP5; Santa Cruz Biotechnology) diluted
1:1000 in blocking buffer. The blots were then washed four times
for 10 min in PBS/Tween, after which they were incubated with
peroxidase-labeled secondary goat-antimouse antibody (DAKO)
and diluted 1:1000 in blocking buffer for 1 h at room temperature.
The blots were washed six times for 10 min in PBS/Tween before
protein bands were visualized using Western Lightning Chemilu-
minescence reagent (Perkin-Elmer Life Sciences Inc., Boston, MA)
according to the manufacturer’s manual.
RESULTS
Progesterone Regulation of Gene Expression in
PRAB-36 Cells. To make a first selection of genes that are
regulated by progesterone in endometrial cancer cells, a Human
UniGene 1 microarray analysis (IncyteGenomics Inc.) was per-
formed. Using this array, 
90 genes were identified that were
regulated by the progestagen MPA in the PRAB-36 subcell line
(cutoff set at 1.5-fold up- or down-regulation). Table 1 summa-
rizes the 20 most strongly up-regulated and 20 most strongly
down-regulated genes, grouped by function. A large panel of
these genes encodes for proteins involved in tumor progression,
tissue remodeling, and/or metastasis. From this group we se-
lected 5 genes that are involved in cell-matrix interactions, and
as such in tumor cell invasion and/or metastasis, for additional
investigation. These genes are: CD44, CSPG /Versican, Tenas-
cin-C, Integrin 1, and Fibronectin-1.
Analysis of Expression of CD44, CSPG/Versican, Tena-
scin-C, Integrin- 1, and Fibronectin-1 in Ishikawa Subcell
Lines Expressing PRA and/or PRB. To confirm the mi-
croarray data and to study expression of the selected genes in the
Ishikawa subcell lines, analyses of mRNA and protein expres-
sion were performed. It was observed that there were large
differences in expression of the indicated genes (CD44, CSPG/
Versican, Tenascin-C, Integrin 1, and Fibronectin-1) between
the different PR isoform-expressing subcell lines (Figs. 1 and 2)
in the absence of MPA. Furthermore, as described in detail
below, expression of the majority of these genes was regulated
by MPA. The level of expression of both CD44 and CSPG/
Versican in the absence of MPA is lower in the IKpar and
PRA-1 subcell lines compared with the PRB-1 and PRAB-36
sub-cell lines (Fig. 1, A and B; Fig. 2, C and D). CD44 and
CSPG/Versican show similar regulation patterns in the different
subcell lines. Both genes are down-regulated by MPA in the
PRB-1 and PRAB-36 sub-cell lines at the mRNA level (Fig. 1A
and 1B). At the protein level in PRB-1 and PRAB-36 subcell
lines, deposition of CD44 and CSPG/Versican in the extracel-
lular matrix is clearly reduced when the cells are cultured in the
presence of MPA (Fig. 2, C and D). For the PRA-1 subcell line,
down-regulation by MPA is much less evident. In the IKpar line
there is no evidence of MPA-induced regulation of either genes
at the mRNA or protein level. For Tenascin-C, the Northern
blotting data do not correlate well with the microarray data. The
Northern blot analysis shows only a very low expression and a
weak down-regulation of Tenascin-C in the PRAB-36 subcell
line (Fig. 1C). Expression of Tenascin-C in the absence of MPA
is also very low in the PRB-1 cells, and regulation of expression
by MPA is not detectable (Fig. 1C). However, at the protein
level, expression of Tenascin-C is high, and is down-regulated
by MPA in the PRB-1 and PRAB-36 subcell lines (Fig. 2E). In
the PRA-1 subcell line, the basal mRNA expression of Tenas-
cin-C is high and down-regulation is observed, but at the protein
level expression is low and not regulated by MPA. In the IKpar
line, combined mRNA and protein data show no clear regulation
(Fig. 1C; Fig. 2E). At the mRNA level, basal expression levels
of Integrin-1 expression is similar in all of the subcell lines.
Expression of Integrin-1 is up-regulated by MPA in the PR-
expressing subcell lines on Northern blot (Fig. 1D). The appar-
ent up-regulation of Integrin-1 in the IKpar line is because of
a difference in the amount of RNA loaded onto the gel (Fig. 1F).
At the protein level, Integrin-1 is expressed at high levels in all
of the subcell lines. There is no visible regulation of expression
by MPA (Fig. 2F), but this may be because of the high basal
level of expression. At the mRNA-level, Fibronectin-1 was
expressed at high levels in the PRB-1 and PRAB-36 lines, and
was clearly down-regulated by MPA. In the PRA-1 line, low
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expression but no regulation was observed. In the IKpar line,
expression of Fibronectin-1 was detected, but this was not
regulated by MPA (Fig. 1E). At the protein level, MPA-induced
down-regulation of Fibronectin-1 could be observed only in the
PRAB-36 subcell line (Fig. 2G). This observation was con-
firmed by Western blot (Fig. 2H).
Expression of CD44, CSPG/Versican, Tenascin-C, In-
tegrin 1, and Fibronectin-1 in Endometrial Cancer Tissue
Samples. To study expression of the selected genes in endome-
trial cancer tissue, consecutive sections of formalin-fixed, paraffin-
embedded samples of endometrioid adenocarcinoma were immu-
nohistochemically stained for hPRA  hPRB, CD44, CSPG/
Versican, Tenascin-C, Integrin- 1, and Fibronectin-1. Because
loss of expression of E-cadherin in epithelial tumors strongly cor-
relates with increased tumor cell invasion and metastasis (24), and
is also associated with more aggressive endometrial cancer (25),
this marker was studied as an indicator for potential risk for
invasion and metastasis. Staining for E-cadherin in regions with
decreased PR expression was less intense and was also more evenly
distributed throughout the whole cell instead of being located at the
Table 1 Progesterone-regulated genes in the PRAB-36 cell line
The Ishikawa subcell line PRAB-36 was cultured for 48 h in presence or absence of 107 M MPA. Total RNA was hybridized to a 9600 cDNA
microarray. The 20 most strongly down-regulated genes (left half of the table), and 20 most strongly up-regulated genes (right half of the table) are
listed and grouped by function. Functions of individual genes are summarized briefly. The numbers indicate fold induction (as calculated by the Incyte
GEMTools 2.5.0. software), with negative numbers indicating down-regulation and positive numbers indicating up-regulation.
Tumor progression/tissue remodeling/metastasis
3.2 fibronectin 1 ECM component, cell-matrix
interactions
3.7 collagen type IV, alpha3 cell-matrix interactions
2.4 chondroitin sulfate
proteoglycan 2 (versican)
cell-matrix interactions 3.5 epithelial V-like antigen placental morphogenesis
2.0 tenascin C (hexabrachion) tissue remodeling 3.3 leucocyte cell adhesion
molecule
tumor leukocyte recruitment
2.0 B-cell CLL/lymphoma 1 leukemia 2.4 antileukoproteinase placental development
1.9 urokinase plasminogen
activator
matrix degradation 2.3 BTG family, 2 cell cycle, differentiation
1.7 CD44 cell-matrix interactions 2.1 integrin, beta 1 cell-matrix interactions
1.7 cyclin D1 cell cycle
1.7 CYR61 angiogenesis
1.7 HGF binding protein tumor progression,
angiogenesis
1.6 v-jun avian sarc. virus 17
homologue
oncogenesis
1.6 tissue factor pathway inhibitor
2
vascular remodeling, apoptosis
1.6 claudin 1 tight junction, recruiting MMPs
Signal transduction
2.7 serum-inducible kinase serine/threonine protein kinase 3.5 fatty-acid-Coenzyme A ligase,
long-chain 2
fatty acid synthesis
1.8 aldehyde dehydrogenase 1
family, A1
drug resistance, proliferation 3.3 methionine adenosyltransferase
II, alpha
s-adenosylmethionine synthesis
1.6 UDP-glucose ceramide
glucosyltransferase
glucosphingolipid synthesis 3.1 FK506-binding protein 5 cell signaling, transcription
1.6 G protein-coupled receptor
kinase 5
-adrenergic receptor signaling 2.7 protein fosphatase 2, cat.
subunit  isoform
protein phosphorylation
2.7 serum/glucocorticoid regulated
kinase
serine/threonine protein kinase
2.6 protein fosphatase 1, cat.
subunit,  isoform
serine/threonine phosphatase
2.3 signal recognition particle
54kD
protein targeting to membranes
Ion homeostasis
2.2 salivary proline-rich protein Ca-homeostasis in saliva 3.0 ferritin, heavy polypeptide 1 iron metabolism
1.9 annexin A4 ion channeling 2.5 AHNAK nucleoprotein
(desmoyokin)
Ca-homeostasis
1.8 solute carrier family 7 organic solute transporter 2.4 solute carrier family 22,
member 5
organic cation transporter
Various
4.2 IGFBP3 IGF 1 transporter 3.3 IgM primary antibody response
2.7 IL-1 receptor, type 1 interleukin signaling, innate
immunity
2.2 IFN- receptor 1 co-ordination tumor-immune
responses
2.2 lethal giant larvae homologue 2 cell polarity
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cell surface (Table 2; Fig. 3D). This indicates that during loss of
progesterone responsiveness in endometrial cancer, expression of
functional E-cadherin is also lost.
A representative panel of stainings in consecutive sections
of a well-differentiated, stage Ia tumor (panel I) and an undif-
ferentiated, stage Ic tumor (panel II) is presented in Fig. 3.
Results of all of the stainings are summarized in Table 2. If
within one section, regions were present in which the PR was
differently expressed, the expression of E-cadherin, CD44,
CSPG/Versican, Tenascin-C, Integrin- 1, and Fibronectin-1 is
indicated for these separate regions. It was observed that the
expression of PR in these endometrial tumors decreased with
dedifferentiation. When PR staining was compared with CD44
staining, a strong inverse correlation was observed: in regions
where PR expression was low, expression of CD44 was clearly
increased (Fig. 3B; Table 2). Similar observations were made
for CSPG/Versican expression (Fig. 3C; Table 2). For Tenas-
cin-C, Integrin-1, and Fibronectin-1 immunostaining, there
was no clear correlation with PR expression (Table 2).
DISCUSSION
In endometrial cancer, loss of PR expression is associated
with late-stage disease in which the tumor no longer responds to
progesterone treatment. In this study, we connect in vitro reg-
ulation by progesterone of a selected number of genes, which
are potentially involved in invasion and metastasis, with in vivo
changes in expression of corresponding proteins during endo-
metrial cancer progression.
Metastasis is a multistep process, starting with tumor
cell invasion. This involves detachment of cells from the
primary tumor and migration of tumor cells through the
extracellular matrix (26). During invasion of tumor cells, loss
of cell-cell adhesion, modulation of cell-matrix interactions,
and degradation/remodeling of the extracellular matrix are of
great importance (27). Therefore, molecules that have a func-
tion in these processes are candidate regulators of invasion
and metastasis. When we analyzed which genes were regu-
lated by MPA (which is the progestagen preferably used in
the clinic) in the Ishikawa endometrial cancer subcell line
PRAB-36, it was observed that a large portion of the identi-
fied progesterone-regulated genes encoded for proteins that
are potentially involved in tumor progression and/or inva-
sion/metastasis. For instance, the progesterone down-regu-
lated genes Urokinase plasminogen activator and Claudin-1
cooperate with matrix metalloproteinases in the process of
extracellular matrix degradation (28, 29). Another progester-
one down-regulated gene, CYR61, promotes angiogenesis
(30). In this study, we focus on a panel of five progesterone-
regulated genes that are implicated in cell-matrix interactions
and could, therefore, play a role in tumor cell invasion. These
genes are CD44, CSPG/Versican, Tenascin-C, Integrin 1,
and Fibronectin-1. From the microarray data it became clear
that CD44, CSPG/Versican, Tenascin-C, and Fibronectin-1
were down-regulated by MPA in the PRAB-36 subcell line,
whereas Integrin-1 was up-regulated. The functions of the
proteins encoded by these genes are discussed briefly first.
CD44 is a cell surface molecule, which exists in many
isoforms and is mainly involved in cell-matrix interaction (31).
Fig. 1 Regulation of expression of
CD44, CSPG/Versican, Tenascin-C,
Integrin- 1, and Fibronectin-1
mRNA in the IKpar and PRA and/or
PRB-expressing subcell lines. IKpar,
PRA-1, PRB-1, and PRAB-36 cells
were cultured in the presence of 107
M MPA for 0, 8, 24, 48, and 72 h.
Total RNA was isolated, separated on
agarose gel, blotted, and hybridized
to 32P-labeled cDNA-probes from:
CD44 (A), CSPG/Versican (B), Tena-
scin-C (C), Integrin- 1 (D), and Fi-
bronectin-1 (E). Hybridization to a
32P-labeled actin probe (F) was used
to verify equal loading in the different
lanes of the gel.
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CD44 can promote tumor growth and invasiveness (32), and
over-expression of CD44 is associated with increased metastasis
in endometrial cancers with increased myometrial invasion (25).
CD44 has been implied in regulation of postpartum uterine
involution through association with several matrix metallopro-
teinases (33).
CSPG/Versican is a member of the family of proteoglycans,
which interacts with CD44. CSPG/Versican has been reported to
Fig. 2 Protein expression of PR, CD44, CSPG/Versican, Tenascin-C, Integrin- 1, and Fibronectin-1 in the IKpar, and PRA- and/or PRB-expressing
subcell lines. Ishikawa subcell lines IKpar, PRA-1, PRB-1, and PRAB-36 were cultured in collagen gels, in absence () or presence () of 107 M MPA,
for 72 h. Sections of the formalin-fixed, paraffin-embedded gels were immunohistochemically stained for: hPRA  hPRB (A), hPRB (B), CD44 (C),
CSPG/Versican (D), Tenascin-C (E), Integrin- 1 (F), and Fibronectin-1 (G). Each panel shows one cluster of cells in collagen gel. Original magnification
400. H shows Western blot analysis of expression of Fibronectin-1 after 0, 8, 24, 48, and 72 h of culturing in presence of 107 M MPA.
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mediate tumor cell invasion (34). Also, the CSPG-degrading chon-
droitinases AC and B inhibit invasion of melanoma cells (35).
Tenascin-C plays a role in tissue remodeling during em-
bryonic development and is re-expressed in many different
tumors (36–38). Tenascin-C can stimulate proliferation, but
growth-inhibiting effects have also been reported (37, 38). In
breast cancer, Tenascin-C expression correlates with increased
invasion and is suggested as a prognostic factor for metastasis
(39, 40).
Fibronectin-1 is a major component of the basal lamina. It
has functions in a variety of processes, such as proliferation,
adhesion, and migration (41, 42). Fibronectin-1 mediates cell-
matrix adhesion by interacting with a wide variety of membrane
and matrix components, such as the classic Fibronectin-1 recep-
tor Integrin 51, collagen, and CSPG (41, 43). Dai et al. (44)
also showed recently that Fibronectin-1 was down-regulated by
progesterone in a poorly differentiated endometrial cancer cell
line.
The present observation that MPA down-regulates expres-
sion of CD44, CSPG, Tenascin-C, and Fibronectin-1 in the
PRAB-36 subcell line provides evidence that progesterone
could play an inhibiting role in tumor cell invasion.
In contrast with the four down-regulated genes discussed
above, Integrin-1 was found to be up-regulated by MPA in the
PRAB-36 subcell line. Integrin-1 is located in the plasma
membrane, where it functions as a complex with Integrin
chains. Integrins mediate cell-matrix interactions that are nec-
essary for cell migration and are involved in bidirectional cell
signaling (45). Increased expression of integrins in cancer has
been associated with increased metastasis through various path-
ways (46–49). Therefore, up-regulation of Integrin-1 by MPA
in the PRAB-36 subcell line seems to be in conflict with the
overall invasion- and metastasis-inhibiting effect of MPA in
these cells. However, it has been reported that Integrin-1 can
interact with E-cadherin to inhibit tumor cell detachment and
invasion into the extracellular matrix (50, 51). In this last
setting, the up-regulation of Integrin-1 by MPA in the
PRAB-36 cell line is consistent with the suggested overall
invasion- and metastasis-inhibiting effect of MPA. Expression
of Integrin-1 was reported recently to be strongly down-regu-
lated in poorly differentiated endometrial cancer cells tran-
siently overexpressing hPRB (44).
In the absence of progesterone-regulation, CD44, CSPG/
Versican, Tenascin-C, and Fibronectin-1 show differential
6 Internetaddress:http://www.FIGO.org/content/PDF/corpus-uteri_p47–
49.pdf.
Table 2 Analysis of expression of PR, CD44, CSPG/Versican, Tenascin-C, Integrin1, and Fibronectin-1 in endometrial cancer samples
Summary of immunohistochemical stainings on formalin-fixed, paraffin-embedded samples of hyperplastic endometrium and endometrioid
adenocarcinoma (collected at Erasmus MC 2000–2001). H: hyperplasia, 1: G1 (well-differentiated), 2: G2 (moderately differentiated), 3: G3 (poorly
or undifferentiated). MI: myometrial invasion, defined as less (	), more () or equal to () half (0.5) of the thickness of the myometrium.
Histological typing, grade and stage (according to the modified FIGO staging system; Ref. 23; see also website.6) and extent of myometrial invasion
were assessed by the Erasmus MC Department of Pathology.
MI stage E-cad PR CD44 CSPG Ten Int Fibr
H 0 n.a.a b      
H 0 n.a.       /
H 0 n.a.       
1 0 1a   /  /

 /
1 	0.5 1b       
 /

/   / 
1 	0.5 11a    /   
  / / /

 
1 0.5 1c  /

/ /   /
2 	0.5 1b / /

/  /

/ 
2 0.5 1c       /
2 0.5 1c  /

  /

 
3 0.5 1b / /

    
    /

/ 
3 0.5 1b   /   / 
3 0.5 1c       /
3 0.5 1c    /   /
3 0.5 1c /      
a n.a., not applicable; PR, hPRA  hPRB; E-cad, E-cadherin; CSPG, CSPG/Versican; Ten, Tenascin-C; Int, Integrin-1; Fibr, Fibronectin-1.
b Staining was approximated semiquantitatively at : 80% positive; : 60–80% positive; /: 30–60% positive; : 	30% positive. If
within one section, regions were present in which the PR was differently expressed, the expression of E-cadherin, CD44, CSPG/Versican, Tenascin-C,
Integrin-1, and Fibronectin-1 is indicated for these separate regions.
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expression in the different Ishikawa subcell lines, both at the
mRNA level and at the level of protein expression. Particu-
larly CD44 and CSPG/Versican, and also Fibronectin-1, are
expressed at high levels in the subcell lines that express the
hPRB (PRB-1 and PRAB-36), whereas in the cell lines lack-
ing hPRB (IKpar and PRA-1) the expression of these genes is
much lower. This may indicate that, at least in vitro, endo-
metrial cancer cells that express different PR isoforms will
have a different invasive capacity in the absence of MPA.
From the present results, it can be expected that endometrial
cancer cells that express hPRB may be more invasive than
cells that do not express hPRB.
The observation that MPA down-regulates CD44, CSPG/
Versican, and Fibronectin-1 in the hPRB-expressing subcell lines
(PRB-1 and PRAB-36), but not (in the case of CSPG/Versican and
Fibronectin-1) or to a lesser extent (in the case of CD44) in the
subcell line, which expresses only hPRA (PRA-1), supports the
observations that a different set of genes is regulated by progester-
one in cancer cells that express different PR isoforms (7, 8). From
the observed profile of gene regulation by MPA in the Ishikawa
subcell lines, it is to be expected that progesterone will have an
invasion-inhibiting effect on progesterone-sensitive endometrial
cancer. This is in agreement with the observations of Dai et al. (44),
who showed that in poorly differentiated endometrial cancer cells
transiently expressing hPRB, invasion through Matrigel could be
inhibited by progesterone.
When an endometrial tumor loses expression of PR, it can
be expected that this will result in a loss of progesterone regu-
lation of the genes that are selected in the present study. If this
holds true, one would expect a relative up-regulation of CD44,
CSPG/Versican, Tenascin-C, and Fibronectin-1, and a relative
down-regulation of Integrin-1, in tumors in which expression
of PR is absent. The present study indicates that, in advanced
tumors, loss of PR is strongly associated with increased expres-
sion of CD44 and CSPG/Versican. This is in agreement with the
findings in the Ishikawa cell line model. For expression of
Tenascin-C, Fibronectin-1, and Integrin-1, an association with
expression of PR was not found.
In many epithelial tumors, a major event in the develop-
ment of metastasis is the loss of functional E-cadherin (24).
Cadherins are transmembrane glycoproteins that take part in
calcium-dependent cell-cell adhesion (24, 27, 52). In metastatic
cancer, E-cadherin function is often disturbed, resulting in a loss
of cell-cell adhesion. The present study indicates that if in
endometrial cancer PR expression is decreased, expression of
E-cadherin is also decreased. Additionally, these tumors showed
more extensive myometrial invasion than tumors in which PR is
abundantly expressed. This observation seems to indicate that
loss of PR is a feature of a more invasive phenotype in endo-
metrial cancer.
We conclude that, in addition to the well-known growth-
inhibiting effect of progesterone on endometrial cancer, proges-
terone and its receptors play an important role in regulating
invasive properties of endometrial cancer cells. The genes that
were found to be involved in this process are CD44 and CSPG/
Versican. Loss of PR expression in vivo, which results in loss of
progesterone-regulation of CD44 and CSPG/Versican, may be
5 Because consecutive slides were stained to detect PRAB, CD44,
CSPG/Versican, Tenascin-C, Integrin1, Finbronectin-1, and E-
cadherin (in this order), the section that was stained for E-cadherin is not
directly consecutive.
Fig. 3 Expression of PR, CD44, CSPG/Versican, and E-cadherin in endometrial cancer tissue samples. Sections of formalin-fixed, paraffin-
embedded samples of endometrioid adenocarcinoma were immunohistochemically stained for hPRA  hPRB (A), CD44 (B), CSPG/Versican (C),
and E-cadherin (D). A representative set of stainings in semiconsecutive5 slides of a well-differentiated (G1, stage Ia) tumor sample (I) and an
undifferentiated (G3, stage Ic) tumor sample (II) is shown. Histopathological typing, grade, and stage were assessed by the Erasmus MC Department
of Pathology (according to the modified FIGO staging system; Ref. 23). See also website.6 Original magnification 200.
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an early, and possibly initializing event in the development of a
more invasive phenotype in endometrial cancer.
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